3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
4
Phase 2
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma, Large B-Cell, Diffuse
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Lymphoma
14
Lymphoma, Non-Hodgkin
10
Lymphoma, Follicular
8
Lymphoma, B-Cell
8
Lymphoma, Mantle-Cell
7
Burkitt Lymphoma
7
Rhabdomyosarcoma
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
6
Recurrence
5
Leukemia
5
Immunoblastic Lymphadenopathy
5
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Large-Cell, Anaplastic
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Sarcoma, Ewing
3
Lymphoma, Primary Effusion
3
Sarcoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Osteosarcoma
2
Neuroblastoma
2
Neoplasms
2
Myelodysplastic Syndromes
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell, Marginal Zone
2
Hodgkin Disease
2
Enteropathy-Associated T-Cell Lymphoma
2
Interventions
pembrolizumab
6
aldesleukin
6
Cyclophosphamide
6
fludarabine phosphate
5
fludarabine
5
Nivolumab
4
durvalumab
3
Sorafenib
3
Radiotherapy
3
Filgrastim
3
Everolimus
3
Axitinib
3
Temozolomide
2
Peripheral Blood Stem Cell Transplantation
2
Isotretinoin
2
Ipilimumab
2
Interleukin-2
2
Interferon-alpha
2
Fluorouracil
2
Dexamethasone
2
Cyclosporine
2
Bevacizumab
2
vorolanib
1
tremelimumab
1
tocilizumab
1
talazoparib
1
spartalizumab
1
sargramostim
1
poly ICLC
1
palbociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Kidney Neoplasms
×
Vincristine
×
Clear all
NCT05384821
2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2
Recruiting
28 enrolled